Search
for
Sort by
Research 91–120 of 1000+
- Bimatoprost in the treatment of eyelash hypotrichosis
- Therapeutic, Prophylactic, and Functional Use of Probiotics: A Current Perspective
- Clinical management of patients with<i>ASXL1</i>mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance
- Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids
- Adaptive Triboelectric Nanogenerators for Long-Term Self-Treatment: A Review
- Mutational spectrum associated with oculocutaneous albinism and Hermansky-Pudlak syndrome in nine Pakistani families
- Data-driven strategies for drug repurposing: insights, recommendations, and case studies
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- Efficacy and safety of tofacitinib in patients with alopecia areata
- Dupilumab: A Potential Option for Young Children With Alopecia Areata and Atopic Features
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Alymphoid cystic thymic dysgenesis - FOXN1 gene mutation: a rare case report of two siblings
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- Janus kinase inhibitors in dermatology: A systematic review
- Safety and Efficacy of Bimatoprost Solution 0.03% Topical Application in Patients with Chemotherapy-Induced Eyelash Loss
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- Off-label dermatologic uses of IL-23 inhibitors
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata